Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02823405
Title Neoadjuvant X4P-001 and Pembrolizumab in Patients With Resectable Melanoma (X4P-001-MELA)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors X4 Pharmaceuticals
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Clinical Site Atlanta Georgia 30322 United States Details
Clinical Site Iowa City Iowa 52242 United States Details
Clinical Site Houston Texas 77030 United States Details
Clinical Site Salt Lake City Utah 84112 United States Details
*Shaded cells indicate that there was no data available from for the field